Managed Care - July 2008 - (Page H15) tion in multiple myeloma. Best Pract Res Clin Haemotol. 2007;20:747–759. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108:3289–3294. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup Francais du Myelome. N Engl J Med. 1996;335:91–97. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoetic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–1030. Bladé J, Rosiñol L, Sureda A, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood. 2005;106:3755–3759. Bortezomib (Velcade) [prescribing information]. June 2008. «http://www.velcade.com/full_prescrib_velcade.pdf». Accessed June 24, 2008. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132. Durie BGM. Multiple Myeloma: Cancer of the Bone Marrow. Concise Review of Treatment Options and Patient Handbook. N. Hollywood, Calif.: International Myeloma Foundation. 2007. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209–1218. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up front or rescue treatment? Results of a multicenter sequential randomized trial. Blood. 1998; 92:3131–3136. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943–2950. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755–760. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582–2590. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564–569. Lacy M, Gertz M, Dispenzieri A, et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, and survival. ASH Annual Meeting Abstracts. Blood. 2006;108:798. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003;31:73–80. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102:3447–3454. Mitsiades CS, Mitsiades NS, Richardson PG, et al. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007;101:950–968. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002; 99:4525–4530. NCCN (National Comprehensive Cancer Network). NCCN Practice guidelines in Oncology: Multiple Myeloma-V.1.2008. «http:// www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf». Accessed June 24, 2008. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin, and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755–762. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006a;81:693–703. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed multiple myeloma. Blood. 2005;106: 4050–4053. Rajkumar SV, Jacobus S, Callender N, et al. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4Ao3): a trial coordinated by the Eastern Cooperative Oncology Group. ASH meeting abstract. Blood. 2006b;108:111:799. Rajkumar SV, Jacobus S, Callender N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4Ao3): a trial coordinated by the Eastern Cooperative Oncology Group. ASCO meeting abstract. J Clin Oncol. 2007;25(185):LBA8025. Rajkumar SV, Rosiñol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26:2171–2177. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498. Ries LAG, Melbert D, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2004. SEER Cancer Statistics Review 1975–2004. National Cancer Institute. «http://seer.cancer. gov/csr/1975_2004/results_merged/sect_18_myeloma.pdf.» Accessed June 3, 2008. Shah SR, Tran TM. Lenalidomide in myelodysplastic syndrome and multiple myeloma. Drugs. 2007;67:1869–1881. Wang M, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortez-thal-dex followed by early intensive therapy. Blood. 2005;106:231. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142. Zonder JA, Barlogie B, Durie BGM, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006;108:403–404. Disclosures: Joseph M. Tuscano, MD, has received honoraria from Amgen, Celgene, and Genentech. He reports no real or apparent conflicts of interest with respect to proprietary products mentioned in this article. SUPPLEMENT / HEMATOLOGIC CANCER 15 http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf http://www.velcade.com/full_prescrib_velcade.pdf http://seer.cancer.gov/csr/1975_2004/results_merged/sect_18_myeloma.pdf http://seer.cancer.gov/csr/1975_2004/results_merged/sect_18_myeloma.pdf
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.